Rein Therapeutics Insider Surge: CEO Rickenbach Buys 66% of Stock Amid Positive Buzz and Uncertain Fundamentals
Insider buying spurs confidence in Rein Therapeutics, but investors face volatility as the company’s pipeline and valuation remain uncertain.
3 minutes to read